Chemours sues DuPont; a series of scandals arising from a subsidiary suing its parent company!

“But for DuPont, there were far too many—indeed, even the mildest—recommended solutions,” court documents state. Instead, after installing a $2.3 million system to eliminate one wastewater stream, DuPont decided to shut down that system at the end of 2013. Coincidentally, it was precisely then that DuPont announced its plan to spin off Chemours—a move internally codenamed 'Project Beta.' Project Beta focused on DuPont’s specialty chemicals division—the very unit that “led DuPont to assume numerous environmental liabilities,” including those related to PFAS such as GenX. The documents state: “Since this problem could be conveniently transferred to Chemours, why spend money solving it?” That is exactly what happened. This year, Chemours, the North Carolina Department of Environmental Quality, and Cape Fear River Watch entered into a consent order imposing a $12 million penalty on Chemours. The order requires Chemours to “employ the same technology DuPont had previously refused to install.” When DuPont established Chemours as a subsidiary in the spring of 2015, it knew the Fayetteville plant had been discharging PFAS into the Cape Fear River for over 30 years. Yet, in private corporate discussions, DuPont assured Chemours that cleaning up the Fayetteville plant’s environmental contamination would cost no more than $2 million. That figure is now estimated at $200 million—not including potential penalties from class-action lawsuits. Moreover, Chemours must also spend hundreds of millions of dollars to remediate several sites in New Jersey. DuPont also “shockingly” underestimated the costs of resolving roughly 3,500 lawsuits—brought by residents near DuPont’s Washington Works facility in Ohio/West Virginia whose drinking water had been contaminated with PFAS from plant wastewater discharges. “These are serious cases. Hundreds of plaintiffs have cancer; others suffer from other severe illnesses.” DuPont engaged Deloitte to analyze potential litigation costs; Deloitte estimated DuPont would win 68% of the cases—and that the remaining cases could be resolved “relatively cheaply”: for $128 million, including defense attorneys’ fees. Yet DuPont lost every single case. Within less than two years, juries awarded victims $671 million—more than five times DuPont’s highest estimated liability. DuPont subsequently agreed to share these costs with Chemours. DuPont spun off liabilities from more than 80 plants to Chemours—including litigation expenses related to asbestos and benzene exposure—even though Chemours would not operate most of those plants post-spinoff. Chemours’ legal filings state that DuPont grossly underestimated costs to comply with a Delaware law requiring a spun-off company to be solvent. Had the true potential liabilities been disclosed, it would have been clear that Chemours was virtually insolvent from inception. Additionally, DuPont appointed three executives to Chemours’ early board of directors—ostensibly to represent Chemours in negotiations. Yet the word “negotiation” is forbidden; instead, court documents label it “Orwellian prosperity,” while DuPont itself calls it “calibrations.”

Key issues in litigation concerning liability for securities misrepresentation

Taking Beijing as an example, among first-instance cases involving disputes over civil liability for securities misrepresentation filed within the past five years, all fall under the jurisdiction of the Beijing Financial Court. II. Litigants (A) Plaintiffs eligible to file civil compensation claims for securities misrepresentation: Investors, security holders, trustees, and asset management product managers. Among them, investors and security holders include market participants—such as securities firms, fund management companies, insurance companies, trust companies, and commercial banks—that lawfully establish securities investment products. (B) Liable parties III. Types of Misrepresentation IV. Loss Determination The scope of civil compensation liability borne by the information disclosure obligor is limited to the plaintiff’s actual losses incurred due to the misrepresentation, specifically including: (A) Investment differential loss; (B) Commission (0.03%) and stamp duty (0.1%) attributable to the investment differential loss. In litigation concerning liability for securities misrepresentation, the “Three Dates and One Price” refer to: the date of implementation of the misrepresentation, the date of disclosure (or correction), the benchmark date for calculating investment differential loss, and the benchmark price for calculating investment differential loss. Date of Implementation: The date on which the information disclosure obligor makes the misrepresentation or on which the misrepresentation occurs. Date of Disclosure: The date on which the misrepresentation is first publicly disclosed and becomes known to the securities market via nationally influential media—such as national newspapers, radio or television stations, regulatory agency websites, trading venue websites, major portal sites, or industry-renowned self-media platforms. Benchmark Date: A cutoff date established to reasonably limit the calculation period for losses, thereby confining recoverable damages to losses directly caused by the misrepresentation. In centralized bidding markets, the benchmark date is the date on which cumulative trading volume of the affected securities reaches 100% of their freely tradable shares, commencing from the date of disclosure or correction. If cumulative turnover reaches 100% of freely tradable shares within ten trading days, the tenth trading day is designated the benchmark date; if such turnover is not achieved within thirty trading days, the thirtieth trading day serves as the benchmark date. Benchmark Price: The average closing price of each trading day between the date of disclosure (or correction) and the benchmark date, used as the benchmark price for calculating losses.

Chemours Company Faces Securities Class Action Lawsuit Over Alleged Misleading Statements

3 days ago

Levi & Korsinsky LLP filed a securities class action against Chemours Co., alleging misleading statements on Opteon demand and EBITDA guidance between February and August 2026. Investors with losses during this period are encouraged to contact the firm.

PR Newswire

2026-10-09

Chemours Company Faces Securities Fraud Class Action Over Opteon Demand Claims

2026-10-11

Chemours Faces Securities Lawsuit Over Disclosures and Guidance

2026-10-11

Chemours Company Faces Class Action Lawsuit Alleging Investor Harm

2026-10-12

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.

2026-10-12

Class Action Lawsuit Filed Against Chemours Over Overstated Demand and Lowered 2026 Guidance